
Giampaolo Bianchini
Advertisement
Articles by Giampaolo Bianchini


107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
2
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5
